AB Science specializes in research, development, and sales of kinase protein inhibitors (KPI), therapeutic drugs used in treating cancerous tumors, inflammatory and neuro-degenerative diseases in both humans and animals.

Employees

Sector

Pharmaceuticals

Calendar

10-09 Earnings release - Q2 2026

More about the company

Quarterly revenue - Rate of surprise

Company calendar

Market Closed - OTC Markets 19:57:29 28/05/2026 +03			5-day change	1st Jan Change
1.120 ^USD	-.--%		-.--%	-22.76%

09-11	Certain Ordinary Shares of AB Science S.A. are subject to a Lock-Up Agreement Ending on 11-SEP-2026.	CI
08-17	AB Science completes settlement and delivery of its private placement

Market Cap	46.57M 52.43M 43.55M 39.69M 74.71M 5.05B 75.74M 527M 204M 2.57B 197M 193M 8.26B	P/E 2026 *	-	P/E 2027 *	-
Enterprise Value	46.57M 52.43M 43.55M 39.69M 74.71M 5.05B 75.74M 527M 204M 2.57B 197M 193M 8.26B	EV / Sales 2026 *	38.8x	EV / Sales 2027 *	35.8x
Free-Float	69.03%	Yield 2026 *	-	Yield 2027 *	-

09-11	Certain Ordinary Shares of AB Science S.A. are subject to a Lock-Up Agreement Ending on 11-SEP-2026.	CI
08-17	AB Science completes settlement and delivery of its private placement
08-10	AB Science Wraps Up EUR14 Million Private Placements	MT
08-10	AB Science raises €14.2m
07-13	AB Science to Discontinue Three Masitinib-related Clinical Studies	MT
07-10	AB Science streamlines its portfolio and refocuses on two molecules
07-10	AB Science SA Provides Update on Clinical Program, Suspends Non-Priority Clinical Trials and Focuses on Ab8939 and Masitinib Programs	CI
07-08	Stéphane Ledermann takes the helm at AB Science as CEO
07-07	AB Science S.A. Announces Board Changes	CI
07-07	AB Science S.A. Announces CEO Changes	CI
07-03	AB Science S.A. announced that it has received $2.01616 million in funding	CI
07-01	AB Science, successful private placement
07-01	AB Science S.A. announced that it has received ?2.294 million in funding	CI

09-29	AB Science provides an update on its development plan and financial calendar following a sponsor Good Clinical Practice inspection	GL
08-17	AB Science announces the successful settlement and delivery of securities issued as part of its €14.2 million private placement announced on August 10, 2026	GL
08-10	AB Science announces today the successful completion of capital increases of a total gross amount of EUR 14.2 million	GL
08-04	AB Science : Webconference presentation on masitinib + isoquercetin in COVID-19	PU
07-10	AB Science provides an update on its clinical program, suspending some non-priority clinical trials to focus on two clinical programs	GL

AB Science Stock OTC Markets

Stocks

ABSCF

FR0010557264

Pharmaceuticals

Valuation: AB Science

Chart: AB Science

Latest news: AB Science

Last Transcript: AB Science

Press Releases: AB Science

News in other languages: AB Science

Quotes and Performance

Price Extremes

Managers and Directors: AB Science

Specialty & Advanced Pharmaceuticals

Financials

Company Profile

Quarterly revenue - Rate of surprise

09-29	Bourse : Legrand veut sa part d'IA, Lindt avertit, Shein coule
09-29	AB Science fait le point sur son plan de developpement et son calendrier financier à la suite d'une inspection promoteur des bonnes pratiques cliniques
09-29	L'obligataire fait monter la pression
09-28	Agenda Zonebourse des résultats de sociétés : semaine du 28 septembre au 2 octobre 2026
09-25	Agenda Zonebourse des résultats de sociétés : semaine du 28 septembre au 2 octobre 2026

Current year	1.12	1.37
1 year	1.12	1.45
3 years	0	3.84
5 years	0	16.1
10 years	0	26.7

Manager	Title	Age	Since
Stéphane Ledermann CEO	Chief Executive Officer	-	07/07/2026
Laurent Guy DFI	Director of Finance/CFO	-	20/11/2009
Christian Fassotte CTO	Chief Tech/Sci/R&D Officer	-	01/04/2018

Director	Title	Age	Since
Alain Moussy CHM	Chairman	-	11/07/2001
Patrick Moussy BRD	Director/Board Member	-	20/09/2011
Cécile de Guillebon BRD	Director/Board Member	65	27/06/2021

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
AB SCIENCE	-.--%	-.--%	-	-	53.61M
ELI LILLY AND COMPANY	-0.62%	-0.10%	+50.70%	+114.07%	1,031B
JOHNSON & JOHNSON	-2.30%	-3.90%	+39.50%	+66.07%	638B
ABBVIE INC.	-0.63%	-1.94%	+12.26%	+74.38%	462B
MERCK & CO., INC.	-1.03%	-2.88%	+71.35%	+39.69%	359B
ROCHE HOLDING AG	-0.03%	-3.91%	+34.28%	+39.35%	335B
NOVARTIS AG	-1.58%	+0.39%	+17.92%	+25.77%	273B
ASTRAZENECA PLC	-2.02%	-3.20%	+7.60%	+8.38%	253B
AMGEN INC.	-3.38%	+0.29%	+44.32%	+51.54%	228B
GILEAD SCIENCES, INC.	-1.04%	-2.56%	+32.88%	+96.82%	185B
Average	-1.19%	-0.36%	+34.53%	+57.34%	418.21B
Weighted average by Cap.	-1.06%	-0.35%	+38.05%	+69.18%

	2026 *	2027 *
Net sales	1.2M 1.35M 1.12M 1.02M 1.93M 130M 1.95M 13.58M 5.26M 66.25M 5.07M 4.96M 213M	1.3M 1.46M 1.22M 1.11M 2.09M 141M 2.11M 14.71M 5.69M 71.77M 5.5M 5.38M 231M
Net income	-	-
Net Debt	-	-